Hereditary thrombotic thrombo - cytopenic purpura and the hereditary TTP registry

Hamostaseologie

Volumn 33, Issue 2, 2013, Pages 138-143

  Mansouri Taleghani, M ^a   von Krogh, A S ^b   Fujimura, Y ^c   George, J N ^d   Hrachovinova, I ^e   Knobl P N ^f   Quist Paulsen, P ^b   Schneppenheim, R ^g   Lammle B ^a   Kremer Hovinga, J A ^a  

^a UNIVERSITY OF BERN   (Switzerland)

^b NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^c NARA MEDICAL UNIVERSITY   (Japan)

^d UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^e INSTITUTE OF HEMATOLOGY AND BLOOD TRANSFUSION   (Czech Republic)

^f MEDICAL UNIVERSITY OF VIENNA   (Austria)

^g UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

ADAMTS13; Hereditary thrombotic thrombocytopenic purpura; Upshaw Schulman syndrome

Indexed keywords

VON WILLEBRAND FACTOR CLEAVING PROTEINASE;

ACUTE DISEASE; ARTICLE; DISEASE REGISTRY; ENZYME DEFICIENCY; EVIDENCE BASED PRACTICE; GENE MUTATION; GENETIC DISORDER; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; PLASMA TRANSFUSION; PRACTICE GUIDELINE; RARE DISEASE; RECESSIVE INHERITANCE; THROMBOTIC THROMBOCYTOPENIC PURPURA; ADULT; FEMALE; GENETIC DATABASE; GENETICS; INTERNATIONAL COOPERATION; MALE; PREVALENCE; PURPURA, THROMBOTIC THROMBOCYTOPENIC; REGISTER; RISK FACTOR; STATISTICS AND NUMERICAL DATA; SURVIVAL RATE; REVIEW; STATISTICS;

ADULT; DATABASES, GENETIC; FEMALE; HUMANS; INTERNATIONALITY; MALE; PREVALENCE; PURPURA, THROMBOTIC THROMBOCYTOPENIC; REGISTRIES; RISK FACTORS; SURVIVAL RATE;

EID: 84881504950     PISSN: 07209355     EISSN: None     Source Type: Journal    
DOI: 10.5482/HAMO-13-04-0026     Document Type: Article

References (44)

1. Moake JL. Thrombotic microangiopathies. N Engl J Med 2002; 347: 589-600.
2. Furlan M, Robles R, Solenthaler M et al. Deficient activity of von Willebrand factor-cleaving protease in chronic relapsing thrombotic thrombocytopenic purpura. Blood 1997; 89: 3097-3103.
3. Furlan M, Robles R, Galbusera M et al. Von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolyticuremic syndrome. N Engl J Med 1998; 339: 1578-1584.
4. Tsai HM, Lian EC. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med 1998; 339: 1585-1594.
5. Zheng XL, Sadler JE. Pathogenesis of thrombotic microangiopathies. Annu Rev Pathol 2008; 3: 249-277.
6. Schaller M, Studt JD, Voorberg J, Kremer Hovinga JA. Acquired thrombotic thrombocytopenic purpura. Hämostaseologie 2013; 33: 121-130.
7. Levy GG, Nichols WC, Lian EC, et al. Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature. 2001; 413: 488-494.
8. Schulman I, Pierce M, Lukens A, Currimbhoy Z. Studies on thrombopoiesis. Blood 1960; 16: 943-957.
9. Upshaw JD. Congenital deficiency of a factor in normal plasma that reverses microangiopathic hemolysis and thrombocytopenia. N Engl J Med 1978; 298: 1350-1352.
10. Furlan M, Robles R, Morselli B et al. Recovery and half-life of von Willebrand factor-cleaving protease after plasma therapy in patients with thrombotic thrombocytopenic purpura. Thromb Haemost 1999; 81: 8-13.
11. Barbot J, Costa E, Guerra M, Barreirinho MS et al. Ten years of prophylactic treatment with freshfrozen plasma in a child with chronic relapsing thrombotic thrombocytopenic purpura as a result of a congenital deficiency of von Willebrand factor- cleaving protease. Br J Haematol 2001; 113: 649-651.
12. Meyer SC, Jeddi R, Meddeb B et al. A first case of congenital TTP on the African continent due to a new homozygous mutation in the catalytic domain of ADAMTS13. Ann Hematol 2008; 87: 663-666.
13. Moake JL, Rudy CK, Troll JH et al. Unusually large plasma factor VIII:von Willebrand factor multimers in chronic relapsing thrombotic thrombocytopenic purpura. N Engl J Med 1982; 307: 1432-1435.
14. Furlan M, Robles R, Lämmle B. Partial purification and characterization of a protease from human plasma cleaving von Willebrand factor to fragments produced by in vivo proteolysis. Blood 1996; 87: 4223-4234.
15. Tsai HM. Physiologic cleavage of von Willebrand factor by a plasma protease is dependent on its conformation and requires calcium ion. Blood 1996; 87: 4235-4244.
16. Plaimauer B, Zimmermann K, Volkel D et al. Cloning, expression, and functional characterization of the von Willebrand factor-cleaving protease (ADAMTS13). Blood 2002; 100: 3626-3632.
17. Miyata T, Kokame K, Matsumoto M, Fujimura Y. ADAMTS13 activity and genetic mutations in Japan. Hämostaseologie 2013; 33: 131-137.
18. Schneppenheim R, Kremer Hovinga JA, Becker T et al. A common origin of the 4143insA ADAMTS13 mutation. Thromb Haemost 2006; 96: 3-6.
19. Assink K, Schiphorst R, Allford S et al. Mutation analysis and clinical implications of von Willebrand factor-cleaving protease deficiency. Kidney Int 2003; 63: 1995-9.
20. Manea M, Kristoffersson A, Schneppenheim R et al. Podocytes express ADAMTS13 in normal renal cortex and in patients with thrombotic thrombocytopenic purpura. Br J Haematol 2007; 138: 651-662.
21. Cermakova Z, Hrdlikova R, Sulakova T et al. Thrombotic thrombocytopenic purpura. Prague Med Rep 2009; 110: 239-244.
22. Tao Z, Anthony K, Peng Y et al. Novel ADAMTS-13 mutations in an adult with delayed onset thrombotic thrombocytopenic purpura. J Thromb Haemost 2006; 4: 1931-1935.
23. Camilleri RS, Cohen H, Mackie IJ et al. Prevalence of the ADAMTS-13 missense mutation R1060W in late onset adult thrombotic thrombocytopenic purpura. J Thromb Haemost 2008; 6: 331-338.
24. Moatti-Cohen M, Garrec C, Wolf M et al. Unexpected frequency of Upshaw-Schulman syndrome in pregnancy-onset thrombotic thrombocytopenic purpura. Blood 2012; 119: 5888-5897.
25. Fujimura Y, Matsumoto M, Isonishi A et al. Natural history of Upshaw-Schulman syndrome based on ADAMTS13 gene analysis in Japan. J Thromb Haemost 2011; 9 (Suppl 1): 283-301.
26. Lotta LA, Wu HM, Mackie IJ et al. Residual plasmatic activity of ADAMTS13 is correlated with phenotype severity in congenital thrombotic thrombocytopenic purpura. Blood 2012; 120: 440-448.
27. Furlan M, Lämmle B. Aetiology and pathogenesis of thrombotic thrombocytopenic purpura and haemolytic uraemic syndrome. Best Pract Res Clin Haematol 2001; 14: 437-454.
28. Fujimura Y, Matsumoto M, Kokame K et al. Pregnancy- induced thrombocytopenia and TTP, and the risk of fetal death, in Upshaw-Schulman syndrome. Br J Haematol 2009; 144: 742-754.
29. Meyer SC, Jin S, Cao W, et al. Characterization of five homozygous ADAMTS13 mutations in hereditary thrombotic thrombocytopenic purpura - Towards a phenotype-genotype correlation? ASH Annual Meeting Abstracts 2008; 112: 274.
30. Schneppenheim R, Budde U, Oyen F et al. Von Willebrand factor cleaving protease and ADAMTS13 mutations in childhood TTP. Blood 2003; 101: 1845-1850.
31. Veyradier A, Lavergne JM, Ribba AS et al. Ten candidate ADAMTS13 mutations in six French families with congenital thrombotic thrombocytopenic purpura (Upshaw-Schulman syndrome). J Thromb Haemost 2004; 2: 424-429.
32. Lotta LA, Garagiola I, Palla R et al. ADAMTS13 mutations and polymorphisms in congenital thrombotic thrombocytopenic purpura. Hum Mutat 2010; 31: 11-19.
33. Camilleri RS, Scully M, Thomas M et al. A phenotype- genotype correlation of ADAMTS13 mutations in congenital thrombotic thrombocytopenic purpura patients treated in the United Kingdom. J Thromb Haemost 2012; 10: 1792-1801.
34. Deal T, Kremer Hovinga JA, Marques MB, Adamski J. Novel ADAMTS13 mutations in an obstetric patient with Upshaw-Schulman syndrome. J Clin Apher 2012; doi: 10.1002/jca.21251.
35. Kentouche K, Voigt A, Schleussner E et al. Pregnancy in Upshaw-Schulman syndrome. Hämo - staseologie 2013; 33: 144-148.
36. Noris M, Bucchioni S, Galbusera M et al. Complement factor H mutation in familial thrombotic thrombocytopenic purpura with ADAMTS13 deficiency and renal involvement. J Am Soc Nephrol 2005; 16: 1177-1183.
37. Du VX, van Os G, Kremer Hovinga JA et al. Indications for a protective function of beta2-glycoprotein I in thrombotic thrombocytopenic purpura. Br J Haematol 2012; 159: 94-103.
38. Kokame K, Matsumoto M, Soejima K et al. Mutations and common polymorphisms in ADAMTS13 gene responsible for von Willebrand factor-cleaving protease activity. Proc Natl Acad Sci USA 2002; 99: 11902-11907.
39. Matsumoto M, Kokame K, Soejima K et al. Molecular characterization of ADAMTS13 gene mutations in Japanese patients with Upshaw-Schulman syndrome. Blood 2004; 103: 1305-1310.
40. George JN. How I treat patients with thrombotic thrombocytopenic purpura: 2010. Blood 2010; 116: 4060-4069.
41. Knöbl P. Treatment of thrombotic microangiopathy with a focus on new treatment options. Hämo staseologie 2013; 33: 149-159.
42. Kremer Hovinga JA, Meyer SC. Current management of thrombotic thrombocytopenic purpura. Curr Opin Hematol 2008; 15: 445-450.
43. Antoine G, Zimmermann K, Plaimauer B et al. ADAMTS13 gene defects in two brothers with constitutional thrombotic thrombocytopenic purpura and normalization of von Willebrand factorcleaving protease activity by recombinant human ADAMTS13. Br J Haematol 2003; 120: 821-824.
44. Kremer Hovinga JA, Lämmle B. Role of ADAMTS13 in the pathogenesis, diagnosis, and treatment of thrombotic thrombocytopenic purpura. Hematology Am Soc Hematol Educ Program 2012; 610-616.